A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a first in human study of ETD002 a new drug being developed for the treatment of cystic fibrosis.The study is a randomised, double-blind, placebo-controlled, interventional study to assess the safety and tolerability of ascending single and repeat doses of inhaled ETD002 in healthy male and female subjects.
Epistemonikos ID: a252fc4b3e66c30a693a56678cd111c7a24b2870
First added on: May 07, 2024